NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,338,448 | -19.0% | 170,286 | +2.9% | 0.00% | – |
Q2 2023 | $1,653,046 | +17.6% | 165,470 | +4.5% | 0.00% | – |
Q1 2023 | $1,405,784 | -20.3% | 158,309 | -1.4% | 0.00% | – |
Q4 2022 | $1,762,774 | -14.8% | 160,544 | +1.1% | 0.00% | -100.0% |
Q3 2022 | $2,069,000 | +20.4% | 158,760 | +17.0% | 0.00% | – |
Q2 2022 | $1,719,000 | +17.9% | 135,703 | +30.3% | 0.00% | – |
Q1 2022 | $1,458,000 | -51.6% | 104,122 | +0.1% | 0.00% | -100.0% |
Q4 2021 | $3,011,000 | +2.2% | 104,018 | +5.8% | 0.00% | 0.0% |
Q3 2021 | $2,945,000 | +42.3% | 98,287 | +26.0% | 0.00% | – |
Q2 2021 | $2,070,000 | -0.2% | 78,027 | +17.0% | 0.00% | – |
Q1 2021 | $2,074,000 | +42.2% | 66,698 | +50.3% | 0.00% | – |
Q4 2020 | $1,459,000 | +49.8% | 44,374 | +59.1% | 0.00% | – |
Q3 2020 | $974,000 | – | 27,892 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |